Histone modifications: Implications in renal cell carcinoma

Epigenomics

Volumn 5, Issue 4, 2013, Pages 453-462

  Ramakrishnan, Swathi ^a   Ellis, Leigh ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

DNA methyltransferase; epigenetics; HDAC; histone acetylation; histone methylation; renal cell carcinoma

Indexed keywords

DACINOSTAT; DNA METHYLTRANSFERASE; ENTINOSTAT; HISTONE; HISTONE H3; HISTONE METHYLTRANSFERASE; PANOBINOSTAT; RAPAMYCIN; REPETITIVE DNA; RESVERATROL; ROMIDEPSIN; VALPROIC ACID; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CHROMATIN CONDENSATION; CHROMOSOME CONDENSATION; CPG ISLAND; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HETEROCHROMATIN; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TUMOR SUPPRESSOR GENE; X CHROMOSOME;

EID: 84881097042     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.40     Document Type: Article

References (85)

1. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: Targeting chromatin modifications. Mol. Cancer Ther. 8(6), 1409-1420 (2009
2. Hake SB, Xiao A, Allis CD. Linking the epigenetic language' of covalent histone modifications to cancer. Br. J. Cancer 90(4), 761-769 (2004
3. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part I: Covalent histone modifications. Trends Mol. Med. 13(9), 363-372 (2007
4. Ellinger J, Kahl P, Mertens C et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int. J. Cancer 127(10), 2360-2366 (2010
5. Turner BM. Histone acetylation and an epigenetic code. BioEssays 22(9), 836-845 (2000
6. Iizuka M, Smith MM. Functional consequences of histone modifications. Curr. Opin Genet. Dev. 13(2), 154-160 (2003
7. Grant P. A tale of histone modifications. Genome Biol. 2(4), 3.1-3.6 (2001
8. Milne JC, Denu JM. The Sirtuin family: Therapeutic targets to treat diseases of aging. Curr. Opin Chem. Biol. 12(1), 11-17 (2008
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006
10. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat. Res. 647(1-2), 44-51 (2008
11. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1(3), 143-145 (2005
12. Zeisberg M, Kalluri R. The role of epithelial-To-mesenchymal transition in renal fibrosis. J. Mol. Med. (Berl.) 82(3), 175-181 (2004
13. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100(20), 11606-11611 (2003
14. Sato A, Asano T, Ito K, Sumitomo M, Asano T. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int. 109(8), 1258-1268 (2011
15. Ozdag H, Teschendorff A, Ahmed A et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7(1), 90 (2006
16. Pradhan S, Chin HG, Estève P-O, Jacobsen SE. SET7/9 mediated methylation of non histone proteins in mammalian cells. Epigenetics 4(6), 383-387 (2009
17. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10(7), 457-469 (2010
18. Di Stefano L, Dyson NJ. The emerging roles for histone demethylases in the modulation of signaling pathways. Biomol. Concepts 4(1), 13-27 (2013
19. Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells. Cancer Res. 73(10), 2936-2942 (2013
20. Nightingale KP, O'Neill LP, Turner BM. Histone modifications: Signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin Genet. Dev. 16(2), 125-136 (2006
21. He H, Lehming N. Global effects of histone modifications. Brief. Funct. Genomic. Proteomic. 2(3), 234-243 (2003
22. Bártová E, Krejčí J, Harnič arová A, Galiová G, Kozubek S. Histone modifications and nuclear architecture: A review. J. Histochem. Cytochem. 56(8), 711-721 (2008
23. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3(9), 662-673 (2002
24. Mahalingam D, Medina EC, Esquivel JA et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res. 16(1), 141-153 (2010
25. Latham JA, Dent SYR. Cross-regulation of histone modifications. Nat. Struct. Mol. Biol. 14(11), 1017-1024 (2007
26. Cha TL, Chuang MJ, Wu ST et al. Dual degradation of Aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin. Cancer Res. 15(3), 840-850 (2009
27. Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications. Cell 103(2), 263-271 (2000
28. Peterson CL, Laniel MA. Histones and histone modifications. Curr. Biol. 14(14), R546-R551 (2004
29. Francois F. DNA methylation and histone modifications: Teaming up to silence genes. Curr. Opin Genet. Dev. 15(5), 490-495 (2005
30. Cea M, Soncini D, Fruscione F et al. Synergistic interactions between HDAC and Sirtuin inhibitors in human leukemia cells. PLoS One 6(7), e22739 (2011
31. Lara E, Mai A, Calvanese V et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28(8), 1168-1168 (2009
32. Choi K-C, Jung MG, Lee YH et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 69(2), 583-592 (2009
33. Cui L, Miao J, Furuya T et al. Histone acetyltransferase inhibitor anacardic acid causes changes in global gene expression during in vitro plasmodium falciparum development. Eukaryot. Cell 7(7), 1200-1210 (2008
34. Furdas SD, Kannan S, Sippl W, Jung M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch. Pharm. (Weinheim) 345(1), 7-21 (2012
35. Wagner T, Jung M. New lysine methyltransferase drug targets in cancer. Nat. Biotechnol. 30(7), 622-623 (2012
36. Zagni C, Chiacchio U, Rescifina A. Histone methyltransferase inhibitors: Novel epigenetic agents for cancer treatment. Curr. Med. Chem. 20(2), 167-185 (2013
37. Lohse B, Kristensen JL, Kristensen LH et al. Inhibitors of histone demethylases. Bioorg. Med. Chem. 19(12), 3625-3636 (2011
38. Sayegh J, Cao J, Zou MR et al. Identification of small molecule inhibitors of jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J. Biol. Chem. 288(13), 9408-9417 (2013
39. Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37(4), 391-400 (2005
40. Metzger E, Wissmann M, Yin N et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437(7057), 436-439 (2005
41. Kurdistani SK. Histone modifications as markers of cancer prognosis: A cellular view. Br. J. Cancer 97(1), 1-5 (2007
42. Cheng H-L, Mostoslavsky R, Saito SI et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl Acad. Sci. USA 100(19), 10794-10799 (2003
43. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277(52), 50607-50611 (2002
44. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ. 12(5), 482-491 (2005
45. Kai L, Samuel SK, Levenson AS. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 126(7), 1538-1548 (2010
46. Qian DZ, Kachhap SK, Collis SJ et al Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1a. Cancer Res. 66(17), 8814-8821 (2006
47. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem. 283(52), 36542-36552 (2008
48. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1{alpha} enhances hypoxic gene expression and tumor growth. Mol. Cell. Biol. 30(1), 344-353 (2010
49. Guo X, Shi M, Sun L et al. The expression of histone demethylase JMJD1A in renal cell carcinoma. Neoplasma 58(2), 153-157 (2011
50. Niu X, Zhang T, Liao L et al The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene 31(6), 776-786 (2012
51. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-To-mesenchymal transition induced by TGF-b1 in human renal epithelial cells. J. Am. Soc. Nephrol. 18(1), 58-65 (2007
52. Vanoosten RL, Earel JK Jr, Griffith TS. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 13(6), 628-632 (2006
53. Verheul HMW, Salumbides B, Van Erp K et al. Combination strategy targeting the hypoxia inducible factor-1a with mammalian target of rapamycin and histone deacetylase inhibitors. Clin. Cancer Res. 14(11), 3589-3597 (2008
54. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: A potential target of histone deacetylase inhibitors. J. Urol. 180(3), 1131-1136 (2008
55. Duns G, Van Den Berg E, Van Duivenbode I et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70(11), 4287-4291 (2010
56. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279), 360-363 (2010
57. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331), 539-542 (2011
58. Hakimi AA, Chen Y-B, Wren J et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur. Urol. 63(5), 848-854 (2012
59. Sakurai T, Bilim VN, Ugolkov AV et al. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Biochem. Biophys. Res. Commun. 422(4), 607-614 (2012
60. Shen Y, Guo X, Wang Y et al. Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer 12(1), 470 (2012
61. Richon V, Zhou X, Rifkind R, Marks P. Histone deacetylase inhibitors: Development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol. Dis. 27(1), 260-264 (2001
62. Ajiro K, Nishimoto T. Specific site of histone H3 phosphorylation related to the maintenance of premature chromosome condensation. Evidence for catalytically induced interchange of the subunits. J. Biol. Chem. 260(29), 15379-15381 (1985
63. Tikoo K, Lau SS, Monks TJ. Histone H3 phosphorylation is coupled to poly-(ADP-Ribosylation) during reactive oxygen species induced cell death in renal proximal tubular epithelial cells. Mol. Pharmacol. 60(2), 394-402 (2001
64. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683), 386-389 (1998
65. Majid S, Dar AA, Ahmad AE et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 30(4), 662-670 (2009
66. Touma SE, Goldberg JS, Moench P et al. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin. Cancer Res. 11(9), 3558-3566 (2005
67. Wang X-F, Qian DZ, Ren M et al. Epigenetic modulation of retinoic acid receptor b2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin. Cancer Res. 11(9), 3535-3542 (2005
68. Minardi D, Lucarini G, Filosa A et al. Do DNA-methylation and histone acetylation play a role in clear cell renal carcinoma? Analysis of radical nephrectomy specimens in a long-Term follow-up. Int. J. Immunopathol. Pharmacol. 24(1), 149-158 (2011
69. Rogenhofer S, Kahl P, Holzapfel S, Von Ruecker A, Mueller SC, Ellinger J. Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res. 32(3), 879-886 (2012
70. Mosashvilli D, Kahl P, Mertens C et al. Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 101(12), 2664-2669 (2010
71. Seligson DB, Horvath S, Mcbrian MA et al. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174(5), 1619-1628 (2009
72. Xia W, Nagase S, Montia AG et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 68(6), 1667-1674 (2008
73. Pawłowski R, Mühl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int. J. Cancer 132(2), E11-E17 (2013
74. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012
75. Van Den Berg A, Buys CHCM. Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer 19(2), 59-76 (1997
76. Hakimi AA, Ostrovnaya I, Reva B et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: A report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19(12), 3259-3267 (2013
77. Bernt Kathrin M, Zhu N, Sinha Amit U et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20(1), 66-78 (2011
78. Pajtler K, Weingarten C, Thor T et al. The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. Acta Neuropathol. Comm. 1(1), 19 (2013
79. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-Transcriptional mechanisms. Oncotarget 2(9), 669-683 (2011
80. Mccabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 492(7427), 108-112 (2012
81. Chan K-M, Fang D, Gan H et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27(9), 985-990 (2013
82. Jones J, Juengel E, Mickuckyte A et al. Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J. Cell. Mol. Med. 13(8b), 2342-2352 (2009
83. Kato Y, Yoshimura K, Shin T et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin. Cancer Res. 13(15), 4538-4546 (2007
84. Rogenhofer S, Kahl P, Mertens C et al. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int. 109(3), 459-465 (2011
85. Fritzsche F, Weichert W, Roske A et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8(1), 381 (2008